Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.60 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018389 | 1.00 | GRIN1 (0.60) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL13007746 | 1.00 | GRIN1 (0.60) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL6812629 | 1.00 | GRIN1 (0.60) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL30645499 | 0.83 | GRIN1 (0.58) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL4834976 | 0.81 | GRIN1 (0.56) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL3853829 | 0.81 | GRIN1 (0.41) | GRIN1GRIN2BNR1I3SHBG | |
| SCHEMBL4833938 | 0.81 | GRIN1 (0.56) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL26304098 | 0.81 | GRIN1 (0.41) | GRIN1GRIN2BNR1I3SHBG | |
| SCHEMBL7353210 | 0.80 | GRIN1 (0.55) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL374356 | 0.80 | GRIN1 (0.55) | GRIN1GRIN2BNR1I3CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 605 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120129683-A | Azole derivatives as SHP2 inhibitors | IRBM股份公司 | 2025-06-10 | — | — | CN | claimed |
| CN-119086743-B | Method for simultaneously detecting 16 endocrine disruptors in environmental water body | 江苏省徐州环境监测中心 | 2025-05-23 | — | — | CN | claimed |
| CN-119907692-A | Isolated targeted delivery system for the treatment of gliomas | 塞尔丽思股份公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119894893-A | Sulfone substituted pyrido [3,4-D ] pyrimidine derivatives for the treatment of cancer | 拜耳公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119757729-A | Test paper for detecting diethylstilbestrol and preparation method thereof | 无锡市食品安全检验检测中心 | 2025-04-04 | — | — | CN | claimed |
| CN-119414033-A | Method for establishing hexane estrenol ic-ELISA and application thereof | 周口师范学院 | 2025-02-11 | — | — | CN | claimed |
| CN-119173283-A | Radiopharmaceutical complexes targeting prostate specific membrane antigen and combinations thereof | 拜耳股份有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-119086743-A | Method for simultaneously detecting 16 endocrine disruptors in environmental water body | 江苏省徐州环境监测中心 | 2024-12-06 | — | — | CN | claimed |
| CN-118961985-A | Kit and method for simultaneously detecting 18 steroid hormones based on double-derivative technology | 上海万子健医学检验实验室有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118680938-A | Allyl estrol pharmaceutical composition and preparation method thereof | 常州市第四制药厂有限公司 | 2024-09-24 | — | — | CN | claimed |
| US-20190167604-A1 | ARYLFLUOROSULFATE COMPOUNDS AND METHODS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-06 | — | — | US | claimed |
| EP-3426257-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2019-01-16 | — | — | EP | claimed |
| EP-3310394-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | Sage Therapeutics, Inc. (US) | 2018-04-25 | — | — | EP | claimed |
| US-20170348327-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2017-12-07 | — | — | US | claimed |
| WO-2017156103-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | claimed |
| EP-3191101-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016205721-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2016-12-22 | — | — | WO | claimed |
| WO-2016040322-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| EP-2175277-B1 | ADAM12 as marker for 2nd trimester Down Syndrome | UNIV KOEBENHAVN (DK) | 2013-09-04 | — | — | EP | claimed |
| EP-1901074-B1 | Adam12 as marker for fetal Turner Syndrome | UNIV KOEBENHAVN (DK) | 2011-07-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167604-A1 | ARYLFLUOROSULFATE COMPOUNDS AND METHODS | BRD4, ESR1, NCOA4 | GRIN1 4623/4885GRIN2B 4650/4885NR1I3 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.